Journal of Renal Nutrition
Volume 6, Issue 3 , Pages 127-133 , July 1996

The role of pharmaceutical agents in appetite stimulation in patients with end-stage renal disease

  • Jerrilynn D Burrowes, MS, RD, CS (Research Coordinator)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jerrilynn D. Burrowes, MS, RD, CS, Research Coordinator, Division of Nephrology and Hypertension, Beth Israel Medical Center, 170 East End Ave, 5th Floor, New York, NY 10128.
    • Division of Nephrology and Hypertension, Beth Israel Medical Center, New York, NY, USA.
    • ,
  • Peter A Bluestone, MD (Attending Nephrologist)

      Affiliations

    • Division of Nephrology and Hypertension, Beth Israel Medical Center, New York, NY, USA.

References 

  1. Goldwasser P, Mittman N, Antignani A, et al.  Predictors of mortality in hemodialysis patients. J Am Soc Nephrol. 1993;3:1613–1622
  2. Wolfson M, Strong C, Minturn D, et al.  Nutritional status and lymphocyte function in maintenance hemodialysis patients: An international study. Am J Clin Nutr. 1984;39:547–555
  3. Young GA, Kopple JD, Lindhom B, et al.  Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study. Am J Kidney Dis. 1991;17:462–471
  4. Blagg CR. Importance of nutrition in dialysis patients. Am J Kidney Dis. 1991;17:458–461
  5. Schulman G, Acchiardo S, Diaz-Buxo J, et al.  How important is the problem of malnutrition in chronic dialysis patients. Semin Dial. 1992;5:263–265
  6. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis. 1994;24:1002–1009
  7. Lazarus JM. Nutrition in hemodialysis patients. Am J Kidney Dis. 1993;21:99–105
  8. Kopple JD. Nutrition, diet, and the kidney. In:  Shils ME,  Olson JA,  Shike M editor. Modern Nutrition in Health and Disease. ed 8. Philadelphia: Lea & Febiger; 1995;p. 1102–1134
  9. Bergstrom J. Nutrition and mortality in hemodialysis. J Am Soc Nephrol. 1995;6:1329–1341
  10. Chan A, Cochran C, Harbert G, et al.  Management of hypoalbuminemia: A challenge for the health care team. J Renal Nutr. 1996;6:38–44
  11. Foulks CJ, Goldstein DJ, Kelly MP, et al.  Indications for the use of intradialytic parenteral nutrition in the malnourished hemodialysis patients. J Renal Nutr. 1991;1:23–33
  12. Dombros NV, Digenis GE, Soliman G, et al.  Anabolic steroids in the treatment of malnourished CAPD patients: A retrospective study. Perit Dial Int. 1994;14:344–347
  13. Soliman G, Oreopoulos DG. Anabolic steroids and malnutrition in chronic renal failure. Perit Dial Int. 1994;14:362–365
  14. Ziegler TR, Lazarus JM, Young LS, et al.  Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol. 1991;2:1130–1135
  15. Schulman G, Wingard RL, Hutchinson RL, et al.  The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis. 1993;21:527–534
  16. Kopple JD. The rationale for the use of growth hormone or insulin-like growth factor-1 in adult patients with renal failure. Miner Electrolyte Metab. 1992;18:269–275
  17. Peng SC, Fouque D, Kopple JD. Insulin-like growth factor-1 causes anabolism in malnourished CAPD patients. J Am Soc Nephrol. 1993;4:414; (abstr)
  18. Cooper SJ. Benzodiazepines and appetite: Recent preclinical advances and their clinical implications. Human Psychopharm. 1989;4:81–89
  19. Berridge KC, Pecina S. Benzodiazepines, appetite, and taste palatability. Neurosci Biobehav Rev. 1995;19:121–131
  20. Tayek JA, Heber D, Chlebowski RT, et al.  Effect of hydrazine sulfate on whole body protein breakdown measured by c-lysine metabolism in lung cancer patients. Lancet. 1987;2:241–244
  21. Chlebowski RT, Blucavage L, Grosvenor M, et al.  Hydrazine sulfate in cancer patients with weight loss. Cancer. 1987;59:406–410
  22. Chlebowski RT, Bulcavage L, Grosvenor M, et al.  Hydrazine sulfate: Influence on nutritional status and survival in non-small cell lung cancer. J Clin Oncol. 1990;8:9–15
  23. Kosty M, Fleishman S, Herndon J, et al.  Cisplatin, vinblastine, and hydrazine sulfate in advanced non-small cell lung cancer: A randomized, placebo controlled, double blind phase III study. In: ed 2. Proc Am Soc Clin Oncol. 11:1992;p. 294; (abstr)
  24. Lavenstein AF, Dacaney EP, Lasagna L, et al.  Effect of cyproheptadine on asthmatic children: Study of appetite, weight gain, and linear growth. JAMA. 1972;180:912–916
  25. Halmi KA, Eckert E, Falk JR. Cyproheptadine for anorexia nervosa. Lancet. 1982;1:1357–1358
  26. Halmi KA, Eckert E, LaDu TJ, et al.  Anorexia nervosa: Treatment efficacy of cyproheptadine and amitriptyline. Arch Gen Psychiatry. 1986;43:177–181
  27. Nobel RE. Effect of cyproheptadine on appetite and weight gain in adults. JAMA. 1969;209:2054–2055
  28. Pawlowski GJ. Cyproheptadine: Weight-gain and appetite stimulation in essential anorexic adults. Curr Therap Res Clin Exp. 1975;18:673–678
  29. Kardinal C, Loprinzi CL, Schaid DJ, et al.  A controlied trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer. 1990;65:2657–2662
  30. Tchekmedyian NS. Clinical approaches to nutritional support in cancer. Curr Opin Oncol. 1993;5:633–638
  31. Moertel CG, Schutt AJ, Reitemeier RJ. Corticosteroids therapy of preterminal gastrointestinal cancer. Cancer. 1974;33:1607–1609
  32. Willox JC, Corr J, Shaw J, et al.  Prednisolone as an appetite stimulant in patients with cancer. Br Med J. 1984;228:17–31
  33. Bruera E, Roca E, Cedaro L, et al.  Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep. 1985;69:751–754
  34. Tchekmedyian NS, Halpert C, Ashley J, et al.  Nutrition in advanced cancer: Anorexia as an outcome variable and target of therapy. J Parenter Enteral Nutr. 1992;16:88S–92S
  35. Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care. 1993;9:14–18
  36. Sallan SE, Zinberg NE, Frei E. Antiemetic effects of delta-9-tetrahydrocannabinol in patients receiving chemotherapy. N Engl J Med. 1975;293:795–797
  37. Sallan SE, Cronin C, Zelen M, et al.  Antiemetics in patients receiving chemotherapy for cancer: A randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1990;302:135–138
  38. Eckert H, Waters KD, Jurk IH, et al.  Amelioration of cancer chemotherapy-induced nausea and vomiting by delta-9-tetrahydrocannabinol. Med J Aust. 1979;2:657–659
  39. Chang AE, Shiling DJ, Stillman RC, et al.  Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high dose methotrexate: A prospective randomized evaluation. Ann Intern Med. 1979;91:819–824
  40. Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. J Clin Pharmacol. 1981;21:214–223
  41. Nelson K, Walsh D, Deeter P, et al.  A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care. 1994;10:14–18
  42. Struwe M, Kaempfer SH, Geiger CJ, et al.  Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother. 1993;27:827–831
  43. Rinaldi L. Marijuana: A research overview. Alaska Med. 1994;36:107–113
  44. Plasse TF, Gorter RW, Krasnow SH, et al.  Recent clinical experience with dronabinol. Pharmacol Biochem Behav. 1991;40:695–700
  45. Beal JA. Appetite effect of dronabinol. J Clin Oncol. 1994;12:1524–1525 (letter)
  46. Alexieva-Figusch J, Gilse HA van, Hop WC, et al.  Progestin therapy in advanced breast cancer: Megestrol acetate—an evaluation of 160 treated cases. Cancer. 1980;46:2369–2372
  47. Tchekmedyian NS, Tait N, Moody M, et al.  Appetite stimulation with megestrol acetate in cachectic cancer patients. Semin Oncol. 1986;13:37–43
  48. Aisner J, Tchekmedyian NS, Moody M, et al.  High dose megestrol acetate for the treatment of advanced breast cancer: Dose and toxicities. Semin Hematol. 1987;24:48–55 suppl 1
  49. Tchekmedyian NS, Tait N, Moody M, et al.  High-dose megestrol acetate: A possible treatment for cachexia. JAMA. 1987;257:1195–1198
  50. Muss HB, Case LD, Capizzi RL, et al.  High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1990;8:1797–1805
  51. Aisner J, Parnes H, Tiat N, et al.  Appetite stimulation and weight gain with megestrol acetate. Semin Oncol. 1990;17:2–7
  52. Bruera E, Macmillan K, Kuehn N, et al.  A controlled trial of megestrol acetate on appetite, calorie intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990;66:1279–1282
  53. Loprinzi CL, Schaid DJ, Dose AM, et al.  Bodycomposition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol. 1993;11:152–154
  54. Reitmeier M, Hartenstein RC. Megestrol acetate and determination of body composition by bioelectrical impedance analysis in cancer cachexia. In: ed 2. Proc Am Soc Clin Oncol. 9:1990;p. 325; (abstr)
  55. Tchekmedyian NS, Hickman M, Siau J, et al.  Megestrol acetate in cancer anorexia and weight loss. Cancer. 1992;69:1268–1272
  56. Loprinzi CL, Ellison NM, Schaid DJ, et al.  Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst. 1990;82:1127–1132
  57. Loprinzi CL, Michalak JC, Schaid DJ, et al.  Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol. 1993;11:762–767
  58. Von Roenn JH, Murphy RL, Weber KM, et al.  Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med. 1988;109:840–841
  59. VonRoenn JA, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol. 1990;17:13–16
  60. Summerbell CD, Youle M, McDonald V, et al.  Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD and AIDS. 1992;3:278–280
  61. VonRoenn JH, Armstrong D, Kotler DP, et al.  Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med. 1994;121:393–399
  62. Oster MH, Enders SR, Samuels SJ, et al.  Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med. 1994;121:400–408
  63. Tchekmedyian NS. Treatment of anorexia with megestrol acetate. Nutr Clin Pract. 1993;8:115–118

PII: S1051-2276(96)90050-3

Journal of Renal Nutrition
Volume 6, Issue 3 , Pages 127-133 , July 1996

Article Tools